Home Top Movers What Is Driving Salarius Pharmaceuticals, Inc. (SLRX) Stock Up In Pre-Market Session?

What Is Driving Salarius Pharmaceuticals, Inc. (SLRX) Stock Up In Pre-Market Session?

Shares of biopharma company Salarius Pharmaceuticals, Inc. (SLRX) have been rising +16.58% to $2.25 (as of 09:07 a.m. EST) before the start of the regular session today. The stock has lost -10.65% in the last session closing at $1.93, trading in the range of $1.54 and $2.00 with 2.19 Million shares changed hands.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

What Happened?


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Salarius Pharmaceuticals Inc. is involved in cancer research and developing treatments for cancer patients using the biopharmaceutical industry’s leading-edge technologies. Salarius is investigating seclidemstat, its lead candidate, as a potential treatment for pediatric cancers, solid tumors, and other cancers with treatment options not sufficiently available. The U.S. FDA has already granted Fast Track Designation and Orphan Drug Designation for Seclidemstat for relapsed/refractory Ewing Sarcoma which is in phase 1/2 of clinical trials.

Read More

Salarius today announced the start of the expansion phase of the seclidemstat’s ongoing Phase 1/2 clinical trial in patients with relapsing and refractory (R/R) Ewings and Ewing-related sarcomas. The company will be adopting the following strategy in conducting that expanded study:

  • Under the amended trial protocol, two treatment arms will be included in the expansion stage.
  • Seclidemstat will be studied in combination with topotecan inup to 20 Ewing sarcoma patients in the first arm.
  • Seclidemstat will be investigated as a single agent at the RP2D in patients with Ewing-related sarcomas in the second arm.
  • Salarius expects to report readouts from the trial towards the end of 2021 and into 2022. Both the Ewing and Ewing-related sarcoma arms of the trial will evaluate safety and efficacy endpoints.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

SPX Flow Inc. (FLOW) stock surged during current market. Here’s why the stock is sky-rocketing?

SPX Flow Inc. (NASDAQ: FLOW) stock gained by 24.24% in the current market trading session. SPX FLOW, based in Charlotte, works to make the...

Platinum Group Metal Ltd. (PLG) stock surges during after-market trading. Here’s to know what’s happening?

Platinum Group Metal Ltd. (NASDAQ: PLG) stock declined by 8.54% at last close whereas the PLG stock price gains by 7% in the after-market...

TD Holdings Inc. (GLG) stock gains during current market trading. Here’s the recent update

TD Holdings Inc. (NASDAQ: GLG) stock gains by 5.01% in the current market trading session. TD Holdings, Inc. is a service provider in China...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

NeuroMetrix Inc. (NURO) stock plunged during pre-market. Let’s find out why?

NeuroMetrix Inc. (NASDAQ: NURO) stock gained by 18.89% at last close while the NURO stock price losses by -4.12% in the pre-market trading session....

Related News

Veoneer Inc. (VNE) stock shows massive gains during pre-market. What’s driving it high?

Veoneer Inc. (NASDAQ: VNE) stock decline by 1.82% at the last close whereas the VNE stock price gains by 55.19% in the pre-market trading...

AnPac Bio-Medical Sciences Inc. (ANPC) stock soars during pre-market. Here’s what you should know?

AnPac Bio-Medical Sciences Inc. (NASDAQ: ANPC) stock declined by 4.98% at last close however the ANPC stock price gains by 6.96% in the pre-market...

Endeavour Silver Corp. (EXK) stock surged during pre-market trading. Here’s what you should know?

Endeavour Silver Corp. (NASDAQ: EXK) stock declined by 4.97% at the last close whereas the EXK stock price gains by 3.56% in the pre-market...

Here is why Amneal Pharmaceuticals Inc (AMRX) stock soared on Monday?

Amneal Pharmaceuticals Inc. (AMRX) shares rose 7.18% in after-hours on Monday, July 19, 2021, and closed at $4.63 per share. Earlier in the morning,...

Why Applied DNA Sciences Inc. (APDN) stock had a bad Friday?

Applied DNA Sciences Inc. (APDN) shares fell 5.27% in after-hours on Friday, July 16, 2021, at $5.03 per share. Earlier, APDN's stock lost 2.93%...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam